ArticleAmerican journal of ophthalmology2012
Uveal melanoma: molecular pattern, clinical features, and radiation response.
Article in American journal of ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The Association between Gene Expression Profiling and Regression Rate of Posterior Uveal Melanoma following Proton Beam Irradiation.Ocular oncology and pathology · 2025Article
- Is It Possible to Preserve Vision without Compromising Metastases-Free Survival by Use of Fully Fractionated Stereotactic Radiotherapy for Posterior Choroidal Melanoma?Ocular oncology and pathology · 2024Article
- Comparative Single Vesicle Analysis of Aqueous Humor Extracellular Vesicles before and after Radiation in Uveal Melanoma Eyes.International journal of molecular sciences · 2024Article
- Diagnostic Aqueous Humor Proteome Predicts Metastatic Potential in Uveal Melanoma.International journal of molecular sciences · 2023Article
- Relationship between gene expression profile class and tumor thickness regression after plaque brachytherapy for choroidal melanoma.International journal of retina and vitreous · 2022Article
- Gene Expression Profiling in Uveal Melanoma: Five-Year Prospective Outcomes and Meta-Analysis.Ocular oncology and pathology · 2020Article
- Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5.Ocular oncology and pathology · 2020Article
- Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling.Melanoma management · 2020Article
- CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.Retina (Philadelphia, Pa.) · 2020Article
- Pathologic Features of Tumor Activity and Stability in Uveal Melanoma Specimens after Fractionated CyberKnife Radiosurgery.Pathology oncology research : POR · 2019Article
- Response to "Comparison of Gene Expression Profiling and Chromosome 3 Analysis by Fluorescent in situ Hybridization and Multiplex Ligation Probe Amplification in Fine-Needle Aspiration Biopsy Specimens of Uveal Melanoma".Ocular oncology and pathology · 2018Article
- Extrascleral Tumor Extension Associated with Localized Scleral Melt following Plaque Brachytherapy for Uveal Melanoma: Clinical and Histologic Findings.Ocular oncology and pathology · 2018Article
- Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics.Diagnostic pathology · 2017Article
- Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status.Ocular oncology and pathology · 2017Article
- Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Disparities in Uveal Melanoma: Patient Characteristics.Seminars in ophthalmology · 2016Review
- Gene expression profiling and regression rate of irradiated uveal melanomas.Ophthalmic surgery, lasers & imaging retina · 2015Article
- Uveal melanoma: estimating prognosis.Indian journal of ophthalmology · 2015Review
- Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2014Article
- Thermography in clinical ophthalmic oncology.Arquivos brasileiros de oftalmologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo characterize the clinical spectrum of class 1 and class 2 uveal melanomas and their relationship with intraocular proton radiation response.
designMasked retrospective case series of uveal melanoma patients with fine needle biopsy-based molecular profiles.
methodsA total of 197 uveal melanoma patients from a single institution were analyzed for pathology, clinical characteristics, and response to radiation therapy.
resultsA total of 126 patients (64%) had class 1 tumors and 71 (36%) had class 2 tumors. Patients with class 2 tumors had more advanced age (mean: 64 years vs 57 years; P = .001), had thicker initial mean ultrasound measurements (7.4 mm vs 5.9 mm; P = .0007), and were more likely to have epithelioid or mixed cells on cytopathology (66% vs 38%; P = .0004). Although mean pretreatment and posttreatment ultrasound thicknesses were significantly different between class 1 and class 2 tumors, there was no difference in the mean change in thickness 24 months after radiation therapy (mean difference: class 1 = -1.64 mm, class 2 = -1.47; P = .47) or in the overall rate of thickness change (slope: P = .64). Class 2 tumors were more likely to metastasize and cause death than class 1 tumors (DSS: P < .0001).
conclusionsAt the time of radiation therapy, thicker tumors, epithelioid pathology, and older patient age are significantly related to class 2 tumors, and class 2 tumors result in higher tumor-related mortality. We found no definitive clinical marker for differentiating class 1 and class 2 tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.